Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jean Davignon

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Physiology

Phenotype

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
41
Lussier-Cacan, Suzanne
28
Cohn, Jeffrey
17
Bernier, Lise
17
Tremblay, Michel
15
Minnich, A
9
Giroux, LM
9
Jacques, Hélène
8
Krimbou, Larbi
7
Marcoux, Caroline
6
Mamer, Orval
6
Roy, Madeleine
6
Rodriguez, Claudia
6
Sing, Charles
6
Batal, Rami
6
Boulet, Lucie

Sign-in to see all Coauthors

Publications

TOP 3
Grover Steven A; Kaouache Mohammed; Joseph Lawrence; Barter Philip; Davignon Jean
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Baass Alexis; Dubuc Geneviève; Tremblay Michel; Delvin Edgard E; O'Loughlin Jennifer; Levy Emile; Davignon Jean; Lambert Marie
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Carmel Jean-François; Tarnus Evelyne; Cohn Jeffrey S; Bourdon Emmanuel; Davignon Jean; Bernier Lise
High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jean Davignon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Grover Steven A; Kaouache Mohammed; Joseph Lawrence; Barter Philip; Davignon Jean
Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Archives of internal medicine 2009;169(19):1775-80.
2009: Baass Alexis; Dubuc Geneviève; Tremblay Michel; Delvin Edgard E; O'Loughlin Jennifer; Levy Emile; Davignon Jean; Lambert Marie
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Clinical chemistry 2009;55(9):1637-45.
2009: Carmel Jean-François; Tarnus Evelyne; Cohn Jeffrey S; Bourdon Emmanuel; Davignon Jean; Bernier Lise
High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes.
Journal of cellular biochemistry 2009;106(4):608-17.
2008: Zaid Ahmed; Roubtsova Anna; Essalmani Rachid; Marcinkiewicz Jadwiga; Chamberland Ann; Hamelin Josée; Tremblay Michel; Jacques Hélène; Jin Weijun; Davignon Jean; Seidah Nabil G; Prat Annik
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Hepatology (Baltimore, Md.) 2008;48(2):646-54.
2008: Bernier Lise; Boulet Lucie; Roy Madeleine; Dufour Robert; Larivière François; Davignon Jean
Two new large deletions in the low density lipoprotein receptor (LDLR) gene not revealed by PCR-based molecular diagnosis of familial hypercholesterolemia.
Atherosclerosis 2008;197(1):118-24.
2007: De Windt Aloys; Rai Myriam; Bernier Lise; Thelen Karin; Soini Juhani; Lefebvre Chantal; Chintawar Satyan; Lavigne Jacques; Saarinen Lilli; Kytömäki Leena; Munzer Jon Scott; Lütjohann Dieter; Pandolfo Massimo; Davignon Jean; Seidah Nabil G; Laaksonen Reijo
Gene set enrichment analysis reveals several globally affected pathways due to SKI-1/S1P inhibition in HepG2 cells.
DNA and cell biology 2007;26(11):765-72.
2007: De Windt Aloys; Rai Myriam; Kytömäki Leena; Thelen Karin Maria; Lütjohann Dieter; Bernier Lise; Davignon Jean; Soini Juhani; Pandolfo Massimo; Laaksonen Reijo
Gene set enrichment analyses revealed several affected pathways in Niemann-pick disease type C fibroblasts.
DNA and cell biology 2007;26(9):665-71.
2007: Schouten Olaf; Hoeks Sanne E; Welten Gijs M J M; Davignon Jean; Kastelein John J P; Vidakovic Radosav; Feringa Harm H H; Dunkelgrun Martin; van Domburg Ron T; Bax Jeroen J; Poldermans Don
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
The American journal of cardiology 2007;100(2):316-20.
2007: Blache Denis; Lussier-Cacan Suzanne; Gagnon Jacques; Leon Arthur S; Rao D C; Skinner James S; Wilmore Jack H; Rankinen Tuomo; Bouchard Claude; Davignon Jean
Effect of exercise training on in vitro LDL oxidation and free radical-induced hemolysis: the HERITAGE Family Study.
Antioxidants & redox signaling 2007;9(1):123-30.
2006: Okura Tomohiro; Rankinen Tuomo; Gagnon Jacques; Lussier-Cacan Suzanne; Davignon Jean; Leon Arthur S; Rao D C; Skinner James S; Wilmore Jack H; Bouchard Claude
Effect of regular exercise on homocysteine concentrations: the HERITAGE Family Study.
European journal of applied physiology 2006;98(4):394-401.
2006: Bourdon Emmanuel; Loreau Nadine; Lagrost Laurent; Davignon Jean; Bernier Lise; Blache Denis
Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells.
Free radical biology & medicine 2006;41(5):786-96.
2006: Nissen Steven E; Nicholls Stephen J; Sipahi Ilke; Libby Peter; Raichlen Joel S; Ballantyne Christie M; Davignon Jean; Erbel Raimund; Fruchart Jean Charles; Tardif Jean-Claude; Schoenhagen Paul; Crowe Tim; Cain Valerie; Wolski Kathy; Goormastic Marlene; Tuzcu E Murat;
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA : the journal of the American Medical Association 2006;295(13):1556-65.
2006: Solomon Crina; Bernier Lise; Germain Lucie; Dufour Robert; Davignon Jean
Severe oily ichthyosis in monozygotic twins mimicking Chanarin-Dorfman syndrome but not associated with a mutation of the CGI58 gene.
Archives of dermatology 2006;142(3):402-3.
2005: Bourgault C; Davignon Jean; Fodor George; Gagné Claude; Gaudet Daniel; Genest Jacques; Lavoie Marc-Andre; Leiter Lawrence; McPherson Ruth; Sénécal Martin; Marentette Michael; Sebaldt Rolf J
Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).
The Canadian journal of cardiology 2005;21(13):1187-93.
2005: Bouchard Catherine; Dubuc Geneviève; Davignon Jean; Bernier Lise; Cohn Jeffrey S
Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells.
Atherosclerosis 2005;178(2):257-64.
2005: Davignon Jean
Apolipoprotein E and atherosclerosis: beyond lipid effect.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(2):267-9.
2005: Davignon Jean; Leiter Lawrence A
Ongoing clinical trials of the pleiotropic effects of statins.
Vascular health and risk management 2005;1(1):29-40.
2004: Wassef Hanny; Bernier Lise; Davignon Jean; Cohn Jeffrey S
Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells.
The Journal of nutrition 2004;134(11):2935-41.
2004: Cohn Jeffrey S; Tremblay Michel; Batal Rami; Jacques Hélène; Rodriguez Claudia; Steiner George; Mamer Orval; Davignon Jean
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.
Atherosclerosis 2004;177(1):137-45.
2004: Cohn Jeffrey S; Patterson Bruce W; Uffelman Kris D; Davignon Jean; Steiner George
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.
The Journal of clinical endocrinology and metabolism 2004;89(8):3949-55.
2004: Davignon Jean; Jacob Robert F; Mason R Preston
The antioxidant effects of statins.
Coronary artery disease 2004;15(5):251-8.
2004: Davignon Jean
Emphasis on pleiotropic effects, a new paradigm shift?
Coronary artery disease 2004;15(5):223-5.
2004: Dubuc Geneviève; Chamberland Ann; Wassef Hanny; Davignon Jean; Seidah Nabil G; Bernier Lise; Prat Annik
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(8):1454-9.
2004: Cohn Jeffrey S; Rodriguez Claudia; Jacques Hélène; Tremblay Michel; Davignon Jean
Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE.
Journal of lipid research 2004;45(8):1572-9.
2004: Davignon Jean
Beneficial cardiovascular pleiotropic effects of statins.
Circulation 2004;109(23 Suppl 1):III39-43.
2004: Davignon Jean; Ganz Peter
Role of endothelial dysfunction in atherosclerosis.
Circulation 2004;109(23 Suppl 1):III27-32.
2004: Davignon Jean
The cardioprotective effects of statins.
Current atherosclerosis reports 2004;6(1):27-35.
2003: Mabile Laurence; Lefebvre Chantal; Lavigne Jacques; Boulet Lucie; Davignon Jean; Lussier-Cacan Suzanne; Bernier Lise
Secreted apolipoprotein E reduces macrophage-mediated LDL oxidation in an isoform-dependent way.
Journal of cellular biochemistry 2003;90(4):766-76.
2003: Cianflone Katherine; Phélis Steve; Davignon Jean; Gilfix Brian M
ApoE phenotype influences plasma ASP in hyperapoB subjects.
Atherosclerosis 2003;170(2):285-91.
2003: Cohn Jeffrey S; Batal Rami; Tremblay Michel; Jacques Helene; Veilleux Lyne; Rodriguez Claudia; Mamer Orval; Davignon Jean
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.
Journal of lipid research 2003;44(10):1976-83.
2003: Castilho Lucia Nassi; Chamberland Ann; Boulet Lucie; Davignon Jean; Cohn Jeffrey S; Bernier Lise
Effect of atorvastatin on ApoE and ApoC-I synthesis and secretion by THP-1 macrophages.
Journal of cardiovascular pharmacology 2003;42(2):251-7.
2003: Cohn Jeffrey S; Tremblay Michel; Boulet Lucie; Jacques Hélène; Davignon Jean; Roy Madeleine; Bernier Lise
Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism.
Atherosclerosis 2003;169(1):63-70.
2003: Wang Xingyu; Chauhan Vinita; Nguyen Anh T; Schultz Joshua; Davignon Jean; Young Stephen G; Boren Jan; Innerarity Thomas L; Rutai Hui; Milne Ross W
Immunochemical evidence that human apoB differs when expressed in rodent versus human cells.
Journal of lipid research 2003;44(3):547-53.
2003: Piolot Alain; Blache Denis; Boulet Lucie; Fortin Louis Jacques; Dubreuil Denise; Marcoux Caroline; Davignon Jean; Lussier-Cacan Suzanne
Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health.
The Journal of laboratory and clinical medicine 2003;141(1):41-9.
2002: Cohn Jeffrey S; Tremblay Michel; Batal Rami; Jacques Hélène; Veilleux Lyne; Rodriguez Claudia; Bernier Lise; Mamer Orval; Davignon Jean
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
Journal of lipid research 2002;43(10):1680-7.
2002: Cohn Jeffrey S; Tremblay Michel; Batal Rami; Jacques Hélène; Veilleux Lyne; Rodriguez Claudia; Barrett P Hugh R; Dubreuil Denise; Roy Madeleine; Bernier Lise; Mamer Orval; Davignon Jean
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Journal of lipid research 2002;43(9):1464-71.
2001: Mabile L; Piolot A; Boulet L; Fortin L J; Doyle N; Rodriguez C; Davignon J; Blache D; Lussier-Cacan S
Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects.
The American journal of clinical nutrition 2001;74(4):449-56.
2001: Krimbou L; Marcil M; Davignon J; Genest J
Interaction of lecithin:cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an alpha 2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance.
The Journal of biological chemistry 2001;276(35):33241-8.
2001: Insull W; Koren M; Davignon J; Sprecher D; Schrott H; Keilson L M; Brown A S; Dujovne C A; Davidson M H; McLain R; Heinonen T
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Atherosclerosis 2001;157(1):137-44.
2001: Grewal T; Priceputu E; Davignon J; Bernier L
Identification of a gamma-interferon-responsive element in the promoter of the human macrophage scavenger receptor A gene.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(5):825-31.
2001: Davignon J; Mabile L
[Mechanisms of action of statins and their pleiotropic effects]
Annales d'endocrinologie 2001;62(1 Pt 2):101-12.
2001: Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn J S
Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Metabolism: clinical and experimental 2001;50(1):112-9.
2001: Davignon J
Advances in lipid-lowering therapy in atherosclerosis.
Advances in experimental medicine and biology 2001;498():49-58.
2000: Bourdon E; Loreau N; Davignon J; Bernier L; Blache D
Involvement of oxysterols and lysophosphatidylcholine in the oxidized LDL-induced impairment of serum albumin synthesis by HEPG2 cells.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(12):2643-50.
2000: Marcoux C; Hopkins P N; Wang T; Leary E T; Nakajima K; Davignon J; Cohn J S
Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state.
Journal of lipid research 2000;41(9):1428-36.
2000: Batal R; Tremblay M; Barrett P H; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn J S
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Journal of lipid research 2000;41(5):706-18.
2000: Carmena R; Roy M; Roederer G; Minnich A; Davignon J
Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.
Atherosclerosis 2000;148(1):113-24.
1999: Davignon J; Laaksonen R
Low-density lipoprotein-independent effects of statins.
Current opinion in lipidology 1999;10(6):543-59.
1999: Lussier-Cacan S; Xhignesse M; Kessling A M; Davignon J; Sing C F
Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health.
American journal of epidemiology 1999;150(11):1229-37.
1999: Cohn J S; Marcoux C; Davignon J
Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(10):2474-86.
1999: Davignon J; Cohn J S; Mabile L; Bernier L
Apolipoprotein E and atherosclerosis: insight from animal and human studies.
Clinica chimica acta; international journal of clinical chemistry 1999;286(1-2):115-43.
1999: Gesquière L; Loreau N; Minnich A; Davignon J; Blache D
Oxidative stress leads to cholesterol accumulation in vascular smooth muscle cells.
Free radical biology & medicine 1999;27(1-2):134-45.
1999: Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn J S
Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
Journal of lipid research 1999;40(4):636-47.
1998: Krimbou L; Tremblay M; Davignon J; Cohn J S
Association of apolipoprotein E with alpha2-macroglobulin in human plasma.
Journal of lipid research 1998;39(12):2373-86.
1998: Davignon J; Genest J
Genetics of lipoprotein disorders.
Endocrinology and metabolism clinics of North America 1998;27(3):521-50.
1998: Davignon J; Hanefeld M; Nakaya N; Hunninghake D B; Insull W; Ose L
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
The American journal of cardiology 1998;82(4B):32J-39J.
1998: Marcoux C; Tremblay M; Fredenrich A; Jacques H; Krimbou L; Nakajima K; Davignon J; Cohn J S
Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects.
Atherosclerosis 1998;139(1):161-71.
1998: Grewal T; Boudreau M; Roy M; Chamberland A; Lefebvre C; Lavigne J; Davignon J; Minnich A
Expression of gamma-IFN responsive genes in scavenger receptor over-expressing monocytes is associated with xanthomatosis.
Atherosclerosis 1998;138(2):335-45.
1998: Davignon J
Advances in drug treatment of dyslipidemia: focus on atorvastatin.
The Canadian journal of cardiology 1998;14 Suppl B():28B-38B.
1998: Davignon J; Pearson T A
Beyond LDL-cholesterol: can further reductions in CAD risk be achieved by considering triglycerides?
The Canadian journal of cardiology 1998;14 Suppl B():2B.
1998: Minnich A; Baloukas J; Roederer G; Lussier-Cacan S; Davignon J; Genest J
Lipoprotein lipase gene mutations in coronary artery disease.
The Canadian journal of cardiology 1998;14(5):711-6.
1998: Davignon J
Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.
The American journal of cardiology 1998;81(8A):17F-24F.
1998: Krimbou L; Tremblay M; Jacques H; Davignon J; Cohn J S
In vitro factors affecting the concentration of gamma-LpE (gamma-LpE) in human plasma.
Journal of lipid research 1998;39(4):861-72.
1998: Batal R; Tremblay M; Krimbou L; Mamer O; Davignon J; Genest J; Cohn J S
Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(4):655-64.
1997: Cohn J S; Giroux L M; Fortin L J; Davignon J
Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status, and ApoE phenotype.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2630-7.
1997: Ooi T C; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien P J; Sniderman A D; Tan M H; Tremblay G; Sorisky A; Shurzinske L; Black D M
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(9):1793-9.
1997: Vohl M C; Moorjani S; Roy M; Gaudet D; Torres A L; Minnich A; Gagné C; Tremblay G; Lambert M; Bergeron J; Couture P; Perron P; Blaichman S; Brun L D; Davignon J; Lupien P J; Després J P
Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec.
Clinical genetics 1997;52(1):1-6.
1997: Fredenrich A; Giroux L M; Tremblay M; Krimbou L; Davignon J; Cohn J S
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
Journal of lipid research 1997;38(7):1421-32.
1997: Giroux L M; Cohn J S; LaMarre J; Davignon J
Pseudo type III dyslipoproteinemia is associated with normal fibroblast lipoprotein receptor activity.
Atherosclerosis 1997;132(1):85-94.
1997: Marcoux C; Lussier-Cacan S; Davignon J; Cohn J S
Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects.
Biochimica et biophysica acta 1997;1346(3):261-74.
1997: Levy E; Minnich A; Cacan S L; Thibault L; Giroux L M; Davignon J; Lambert M
Association of an exon 3 mutation (Trp66-->Gly) of the LDL receptor with variable expression of familial hypercholesterolemia in a French Canadian family.
Biochemical and molecular medicine 1997;60(1):59-69.
1997: Krimbou L; Tremblay M; Davignon J; Cohn J S
Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE.
Journal of lipid research 1997;38(1):35-48.
1996: Davignon J
A lipid clinic associated with a research laboratory working on dyslipoproteinemias and atherosclerosis.
The Canadian journal of cardiology 1996;12(10):885-90.
1996: Lussier-Cacan S; Xhignesse M; Piolot A; Selhub J; Davignon J; Genest J
Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits.
The American journal of clinical nutrition 1996;64(4):587-93.
1996: Davignon J; Cohn J S
Triglycerides: a risk factor for coronary heart disease.
Atherosclerosis 1996;124 Suppl():S57-64.
1996: Giry C; Giroux L M; Roy M; Davignon J; Minnich A
Characterization of inherited scavenger receptor overexpression and abnormal macrophage phenotype in a normolipidemic subject with planar xanthomas.
Journal of lipid research 1996;37(7):1422-35.
1996: Guillaume D; Bertrand P; Dea D; Davignon J; Poirier J
Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations.
Journal of neurochemistry 1996;66(6):2410-8.
1996: Marcil M; Boucher B; Gagné E; Davignon J; Hayden M; Genest J
Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects.
Journal of lipid research 1996;37(2):309-19.
1996: Bétard C; Kessling A M; Roy M; Davignon J
Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect.
Atherosclerosis 1996;119(1):43-55.
1996: Cohn J S; Tremblay M; Amiot M; Bouthillier D; Roy M; Genest J; Davignon J
Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(1):149-59.
1996: Carmena R; Lussier-Cacan S; Roy M; Minnich A; Lingenhel A; Kronenberg F; Davignon J
Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(1):129-36.
1995: Poirier J; Minnich A; Davignon J
Apolipoprotein E, synaptic plasticity and Alzheimer's disease.
Annals of medicine 1995;27(6):663-70.
1995: Minnich A; DeLangavant G; Lavigne J; Roederer G; Lussier-Cacan S; Davignon J
G-->A substitution at position -75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(10):1740-5.
1995: Sass C; Giroux L M; Lussier-Cacan S; Davignon J; Minnich A
Unexpected consequences of deletion of the first two repeats of the ligand-binding domain from the low density lipoprotein receptor. Evidence from a human mutation.
The Journal of biological chemistry 1995;270(42):25166-71.
1995: Ferrières J; Lambert J; Lussier-Cacan S; Davignon J
Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.
Circulation 1995;92(3):290-5.
1995: Campos H; Roederer G O; Lussier-Cacan S; Davignon J; Krauss R M
Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(8):1043-8.
1995: Marcil M; Boucher B; Krimbou L; Solymoss B C; Davignon J; Frohlich J; Genest J
Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(8):1015-24.
1995: Sass C; Giroux L M; Ma Y; Roy M; Lavigne J; Lussier-Cacan S; Davignon J; Minnich A
Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia.
Human genetics 1995;96(1):21-6.
1995: Dalery K; Lussier-Cacan S; Selhub J; Davignon J; Latour Y; Genest J
Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate.
The American journal of cardiology 1995;75(16):1107-11.
1995: Minnich A; Roy M; Chamberland A; Lavigne J; Davignon J
New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia.
Clinical biochemistry 1995;28(3):277-84.
1995: McNicoll S; Latour Y; Rondeau C; Bouthillier D; Davignon J; Genest J
Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II.
The Canadian journal of cardiology 1995;11(2):109-16.
1995: Minnich A; Weisgraber K H; Newhouse Y; Dong L M; Fortin L J; Tremblay M; Davignon J
Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
Journal of lipid research 1995;36(1):57-66.
1995: Minnich A; Kessling A; Roy M; Giry C; DeLangavant G; Lavigne J; Lussier-Cacan S; Davignon J
Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent.
Journal of lipid research 1995;36(1):117-24.
1994: Ferrières J; Sing C F; Roy M; Davignon J; Lussier-Cacan S
Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(10):1553-60.
1994: Karayan L; Qiu S; Betard C; Dufour R; Roederer G; Minnich A; Davignon J; Genest J
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(8):1258-63.
1994: Dallongeville J; Leboeuf N; Blais C; Touchette J; Gervais N; Davignon J
Short-term response to dietary counseling of hyperlipidemic outpatients of a lipid clinic.
Journal of the American Dietetic Association 1994;94(6):616-21.
1994: Naruszewicze M; Giroux L M; Davignon J
Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a).
Chemistry and physics of lipids 1994;67-68():167-74.
1993: Lussier-Cacan S; Dubreuil-Quidoz S; Roederer G; Leboeuf N; Boulet L; de Langavant G C; Davignon J; Naruszewicz M
Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(12):1790-7.
1993: Davignon J; Roy M
Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a "founder effect".
The American journal of cardiology 1993;72(10):6D-10D.
1993: Carmena R; Roederer G; Mailloux H; Lussier-Cacan S; Davignon J
The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
Metabolism: clinical and experimental 1993;42(7):895-901.
1993: Selinger E; Dallongeville J; Davignon J
Apolipoprotein(a) is present in the triglyceride-rich fraction in type IV hypertriglyceridemia.
Clinical biochemistry 1993;26(1):59-64.
1993: Giroux L M; Davignon J; Naruszewicz M
Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.
Biochimica et biophysica acta 1993;1165(3):335-8.
1992: Naruszewicz M; Selinger E; Dufour R; Davignon J
Probucol protects lipoprotein (a) against oxidative modification.
Metabolism: clinical and experimental 1992;41(11):1225-8.
1992: Naruszewicz M; Selinger E; Davignon J
Oxidative modification of lipoprotein(a) and the effect of beta-carotene.
Metabolism: clinical and experimental 1992;41(11):1215-24.
1992: Davignon J; Montigny M; Dufour R
HMG-CoA reductase inhibitors: a look back and a look ahead.
The Canadian journal of cardiology 1992;8(8):843-64.
1992: Dallongeville J; Selinger E; Davignon J; Lussier-Cacan S
Fish-oil supplementation reduces Ip(a) concentrations in type III dysbetalipoproteinemia.
Clinical chemistry 1992;38(8 Pt 1):1510-1.
1992: Davignon J; Dufour R; Roy M; Bétard C; Ma Y; Ouellette S; Boulet L; Lussier-Cacan S
Phenotypic heterogeneity associated with defective apolipoprotein B-100 and occurrence of the familial hypercholesterolemia phenotype in the absence of an LDL-receptor defect within a Canadian kindred.
European journal of epidemiology 1992;8 Suppl 1():10-7.
1992: Blache D; Bouthillier D; Davignon J
Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalization by aspirin.
Atherosclerosis 1992;93(3):179-88.
1992: Dallongeville J; Lussier-Cacan S; Davignon J
Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis.
Journal of lipid research 1992;33(4):447-54.
1992: McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
Clinical therapeutics 1992;14(2):276-91.
1992: Bétard C; Kessling A M; Roy M; Chamberland A; Lussier-Cacan S; Davignon J
Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians.
Human genetics 1992;88(5):529-36.
1992: Dallongeville J; Davignon J; Lussier-Cacan S
ACAT activity in freshly isolated human mononuclear cell homogenates from hyperlipidemic subjects.
Metabolism: clinical and experimental 1992;41(2):154-9.
1992: Kessling A; Ouellette S; Bouffard O; Chamberland A; Bétard C; Selinger E; Xhignesse M; Lussier-Cacan S; Davignon J
Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones.
American journal of human genetics 1992;50(1):92-106.
1991: Luc G; Bard J M; Lussier-Cacan S; Bouthillier D; Parra H J; Fruchart J C; Davignon J
High-density lipoprotein particles in octogenarians.
Metabolism: clinical and experimental 1991;40(12):1238-43.
1991: Bielmann P; Leduc G; Thibault G; Lepage J; Davignon J
Effects of chlorthalidone and metoprolol alone or in combination (logroton) on blood pressure, lipids, lipoproteins and circulating plasma ANF levels in essential hypertension.
International journal of clinical pharmacology, therapy, and toxicology 1991;29(12):479-85.
1991: Lussier-Cacan S; Xhignesse M; Desmarais J L; Davignon J; Kafrissen M E; Chapdelaine A
Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
Metabolism: clinical and experimental 1991;40(8):849-54.
1991: Dallongeville J; Boulet L; Davignon J; Lussier-Cacan S
Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(4):864-71.
1991: Xhignesse M; Lussier-Cacan S; Sing C F; Kessling A M; Davignon J
Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(4):1100-10.
1991: Mailly F; Xu C F; Xhignesse M; Lussier-Cacan S; Talmud P J; Davignon J; Humphries S E; Nestruck A C
Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects.
Journal of lipid research 1991;32(4):613-20.
1991: Davignon J; Dallongeville J; Roederer G; Roy M; Fruchart J C; Kessling A M; Bouthillier D; Lussier-Cacan S
A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect.
Annals of medicine 1991;23(2):161-7.
1991: Dallongeville J; Roy M; Leboeuf N; Xhignesse M; Davignon J; Lussier-Cacan S
Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(2):272-8.
1991: Davignon J
Familial hypercholesterolemia: a treatable lethal disease.
The Canadian journal of cardiology 1991;7(1):VI-VII.
1990: Innerarity T L; Mahley R W; Weisgraber K H; Bersot T P; Krauss R M; Vega G L; Grundy S M; Friedl W; Davignon J; McCarthy B J
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.
Journal of lipid research 1990;31(8):1337-49.
1990: Fugère P; Percival-Smith R K; Lussier-Cacan S; Davignon J; Farquhar D
Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component.
Contraception 1990;42(2):225-34.
1990: Bielmann P; Leduc G; Gutkowska J; Davignon J
Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension.
Journal of clinical pharmacology 1990;30(5):438-43.
1990: Mailly F; Davignon J; Nestruck A C
Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma.
Journal of lipid research 1990;31(1):149-55.
1990: Lussier-Cacan S; Nestruck A C; Arslanian H; Xhignesse M; Davignon J; Kafrissen M E; Chapdelaine A
Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins.
Fertility and sterility 1990;53(1):28-34.
1990: Dallongeville J; Davignon J; Lussier-Cacan S
Relationship between plasma cholesterol levels and cholesterol esterification in isolated human mononuclear cells.
Life sciences 1990;47(25):2351-7.
1989: Ma Y H; Bétard C; Roy M; Davignon J; Kessling A M
Identification of a second "French Canadian" LDL receptor gene deletion and development of a rapid method to detect both deletions.
Clinical genetics 1989;36(4):219-28.
1989: Lussier-Cacan S; Bard J M; Boulet L; Nestruck A C; Grothé A M; Fruchart J C; Davignon J
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
Atherosclerosis 1989;78(2-3):167-82.
1989: Davignon J; Fortin L J; Tremblay M; Bouthillier D; Nestruck A C
An unusual band that binds hemoglobin after ultracentrifugation of hemolyzed plasma for lipoprotein separation.
Clinical chemistry 1989;35(3):495.
1989: Weisgraber K H; Newhouse Y M; Taylor J M; Tuan B; Nestruck A C; Davignon J; Mahley R W
Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Arteriosclerosis (Dallas, Tex.) 1989;9(1):50-7.
1988: Davignon J; Xhignesse M; Roederer G
Identification of the patient at risk in the physician's office and drug management of dyslipoproteinemia.
The Canadian journal of cardiology 1988;4 Suppl A():36A-47A.
1988: Davignon J; Gregg R E; Sing C F
Apolipoprotein E polymorphism and atherosclerosis.
Arteriosclerosis (Dallas, Tex.) 1988;8(1):1-21.
1988: Davignon J; Bouthillier D; Nestruck A C; Sing C F
Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians.
Transactions of the American Clinical and Climatological Association 1988;99():100-10.
1987: Roederer G O; Bouthillier D; Davignon J
Xanthelasma palpebrarum and corneal arcus in octogenarians.
The New England journal of medicine 1987;317(27):1740.
1987: Nestruck A C; Bouthillier D; Sing C F; Davignon J
Apolipoprotein E polymorphism and plasma cholesterol response to probucol.
Metabolism: clinical and experimental 1987;36(8):743-7.
1986: Lussier-Cacan S; Cantin M; Roy C C; Sniderman A D; Nestruck A C; Davignon J
Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia.
Clinical and investigative medicine. Médecine clinique et experimentale 1986;9(2):94-9.
1986: Davignon J; Nestruck A C; Alaupovic P; Bouthillier D
Severe hypoalphalipoproteinemia induced by a combination of probucol and clofibrate.
Advances in experimental medicine and biology 1986;201():111-25.
1985: Lussier-Cacan S; Bouthillier D; Davignon J
Apo E allele frequency in primary endogenous hypertriglyceridemia (type IV) with and without hyperapobetalipoproteinemia.
Arteriosclerosis (Dallas, Tex.) 1985;5(6):639-43.
1984: Nestruck A C; Huang Y S; Eid K; Dufour R; Boulet L; Barbeau A; Davignon J
Plasma cholesteryl sulfate in Friedreich's ataxia.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1984;11(4 Suppl):631-6.
1984: Bouthillier D; Nestruck A C; Milne R; Sing C F; Barbeau A; Davignon J
Distribution of apolipoprotein E phenotypes in Friedreich's ataxia.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1984;11(4 Suppl):626-30.
1983: Blache D; Bouthillier D; Davignon J
Simple, reproducible procedure for selective measurement of lipoprotein lipase and hepatic lipase.
Clinical chemistry 1983;29(1):154-8.
1983: Davignon J; Bouthillier D; Dufour R; Lussier-Cacan S
[Xanthoma and atherosclerosis in the presence of normal plasma lipids]
Annales de médecine interne 1983;134(5):483-91.
1982: Blache D; Bouthillier D; Barbeau A; Davignon J
Plasma lipoprotein lipase and hepatic lipase activities in Friedreich's ataxia.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1982;9(2):191-4.
1982: Davignon J; Lussier-Cacan S; Dubreuil-Quidoz S; LeLorier J
Experience with probucol in the treatment of hypercholesterolemia.
Artery 1982;10(1):48-55.
1980: Bielmann P; Leduc G; Davignon J
[Selective beta blockaders (metoprolol) versus non selective (propranolol): comparative effects on the composition of lipoprotein fractions and on blood pressure]
L'unión médicale du Canada 1980;109(12):1734-40.
1980: Enjalbert M; Lussier-Cacan S; DuBreuil-Quidoz S; LeLorier J; Davignon J
Usefulness of probucol in treating primary hypercholesterolemia.
Canadian Medical Association journal 1980;123(8):754-7.
1980: Davignon J; Leboeuf N; Lussier-Cacan S
[Nutritional aspects of managing hyperlipidemias and atherosclerosis]
L'unión médicale du Canada 1980;109(5):656-65.
1980: Bielmann P; Leduc G; Germain M; Davignon J
Beta-blockers and changes in lipoprotein fractions.
The New England journal of medicine 1980;302(5):298.

Sign-in to see more